ReviewClinical cancer research : an official journal of the American Association for Cancer Research2020
Mutated RAS: Targeting the "Untargetable" with T Cells.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 55 citations in OpenAlex.
- Molecular origin, discovery, validation and application of neoantigens.Asian journal of pharmaceutical sciences · 2026Review
- Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma.World journal of gastrointestinal oncology · 2025Review
- A Novel Prognostic Risk-Scoring Model Based on RAS Gene-Associated Cluster in Pediatric Acute Myeloid Leukemia.Cancer medicine · 2025Article
- Comparative Efficacy of Adagrasib and Sotorasib in KRAS G12C-Mutant NSCLC: Insights from Pivotal Trials.Cancers · 2024Article
- Targeting KRASDrugs · 2024Review
- Identification and affinity enhancement of T-cell receptor targeting a KRASCommunications biology · 2024Article
- Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer throughOncology research · 2024Article
- Targeting the 'Undruggable' Driver Protein, KRAS, in Epithelial Cancers: Current Perspective.Cells · 2023Review
- [Preclinical study of T cell receptor specifically reactive withBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2022Article
- Therapeutic high affinity T cell receptor targeting a KRASNature communications · 2022Article
- Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.Cancer discovery · 2022Review
- Mechanism of activation and the rewired network: New drug design concepts.Medicinal research reviews · 2022Review
- High tumor mutation burden indicates better prognosis in colorectal cancer patients withFrontiers in oncology · 2022Article
- Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.Cell reports methods · 2021Article
- Targeting neoantigens for cancer immunotherapy.Biomarker research · 2021Review
- The therapeutic potential of multiclonal tumoricidal T cells derived from tumor infiltrating lymphocyte-1derived iPS cells.Communications biology · 2021Article
- Targeting public neoantigens for cancer immunotherapy.Nature cancer · 2021Review
- Inhibition of Nonfunctional Ras.Cell chemical biology · 2021Review
- Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients.Journal of translational medicine · 2021Article
- Targeting KRAS in Non-Small Cell Lung Cancer.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The RAS family of proteins is at the apex of several pathways implicated in a multitude of epithelial cancers but has remained stubbornly resistant to the wave of targeted small molecules and antibodies that have revolutionized clinical oncology. KRAS, the most commonly mutated of the isoforms, represents an attractive target for treatment, given its ubiquity, central role as a driver mutation, and association with poor prognosis. This review is a comprehensive summary of the existing approaches to targeting KRAS spanning small-molecule inhibitors, cancer vaccines, and with a focus on trials in adoptive cell therapy. Here we explain how the limitations of existing drugs and nonspecific immune-based therapies are circumvented with techniques in modern immunotherapy. The successes outlined represent the most promising path to finally targeting the prototypical "undruggable" RAS oncogene family.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.